Breast cancer survivor offers wisdom at Faulkner satellite center
Call 877-422-3324 today to make an appointment
Make your appointment or second opinion with Dana-Farber today to meet with an onsite specialist.
Can’t get to Boston? Explore our Online Second Opinion service to get expert advice from Dana-Farber oncologists.
Toll-Free Number866-408-DFCI (3324)
Discover the ways to give and how to get involved to support Dana-Farber.
Poet Richard Fox gains insight – and material – through cancer treatment
A family faces cancer in an unfamiliar city – with help
Choosing mastectomy or not: Studying young women's surgical choices
Jeff's targeted therapy has kept his advanced lung cancer at bay.
"Beige fat" cells found in healthy subcutaneous fat play a critical role in protecting the body against the disease risks of obesity in mice, report researchers at Dana-Farber Cancer Institute, who say their study findings may have implications for therapy of obesity-related illness in humans.
A report in the journal Cell suggests that the presence of beige fat, a type of fat cell that can burn energy to release heat, is what makes subcutaneous obesity relatively healthy compared with visceral fat inside the abdomen, which largely lacks beige fat cells and is associated with increased risks of diabetes, heart disease and death.
Excess calories in overweight people are stored in fatty tissues mainly composed of white fat cells. Beige fat is present in scattered deposits in adult humans, mixed in with white fat. Beige cells can activate a “thermogenic” mechanism that burns stored fat to make heat. When this occurs within white fat, the process is called "browning." Bruce Spiegelman, PhD, and Paul Cohen, MD, PhD, of Dana-Farber, led the study.
"The findings indicate that PRDM16 and beige adipocytes [fat cells] are required for the 'browning' of white fat and the healthful effects of subcutaneous adipose tissue," said the authors. In the future, the discovery “might lead to pharmacologic strategies to treat obesity-related diseases,” said Paul Cohen, MD, PhD, the study’s first author. "The goal would be to create healthier fat" — possibly by manipulating PRDM16 in the body, he said.
Spiegelman's research group has been at the forefront of discoveries in the past 20 years about how different types of fat cells emit chemical signals that influence body metabolism, in some instances promoting health and in others disrupting metabolism, leading to diseases like diabetes, hypertension, fatty liver and heart disease. "Fat cells are the central signaling system to measure how much energy is in your body and what the body needs to do about it," he explained.
Cohen, a cardiologist and postdoctoral fellow in the Spiegelman lab, was interested in the function of beige fat in a physiological context as well as the well-known observation that overweight people whose extra pounds are deposited mainly as visceral fat inside the abdomen, around the liver and other organs, have increased risks of high blood pressure, diabetes, and heart disease. Yet people who carry extra weight subcutaneously under the skin of the hips and thighs (a pear-shaped pattern) are largely spared these added risks.
The answers to this discrepancy in the health effects of subcutaneous versus visceral fat have been elusive. Cohen said previous research had found that subcutaneous fat was more prone to browning while visceral fat cells were marked by inflammation and invasion by immune cells. An aim of the new study was to look for differences in gene expression between subcutaneous and visceral fat cells.
Spiegelman and others have proposed that increasing the amount or the activity of beige fat in people might be useful in treating diseases related to being overweight and obese. Skeptics have argued that beige fat is of minor importance in the overall metabolism of the body.
The new research suggests otherwise, demonstrating that beige fat cells "make an important contribution to the whole body physiology of mice," noted the authors.
"Identification of pharmacological activators of PRDM16 targeted to beige adipocytes could hold promise as a new class of therapeutics," they suggested.
Support for the research was provided by National Institutes of Health grants DK040936, DK45735, DK092541, and DK031405.